References
- Madsen J. D., Hoffart A. Psychotherapy with the aid of LSD. Nord J Psychiatry 1996; 50: 477–86
- Robak O. H. LSD-25 som psykoterapeutisk hjel-pemiddel (English summary: LSD-25 as an adjunct to psychotherapy.). Tidsskr Nor Laegeforening 1962; 20
- Johnsen G. Three years experience with the use of LSD as an aid in psychotherapy. Acta Psychiatr Scand 1964; 40 Suppl 180: 383–8
- Aarsberetning, Modum Bads Nervesanatorium 1964
- Letters from the European Medical Society of Psycholytic Therapy (President, Professor Hanscarl Leuner). to Gordon Johnsen 1967-69
- Ergebnisse und probleme der Psychotherapie mit Hilfe von LSD-25 und verwandten Substanzen. Psychiatr Neurol 1962; 143: 379–91
- Cohen S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 1960; 139: 30–40
- Retterstøl N. Hallusinogener. Tidsskr Nor Laegeforen 1966; 1
- Manual of The International Classification of Diseases ICD 7 1955. WHO, Geneva 1957
- Yensen R. LSD and psychotherapy. J Psychoact Drugs 1985; 17: 267–77
- Strassman R. J. Hallucinogenic drugs in psychiatric research and treatment. Nerv Ment Dis 1995; 183: 127–38
- Hausner M., Dolezal V. Follow-up evaluation of LSD psychotherapy of inpatients. Act Nerv Super 1968; 10: 282–3
- Geert-Jörgensen E., Hertz M., Knudsen K., Kristen-Sen KK. LSD-treatment. Experience gained within a three-year-period. Acta Psychiatr Scand 1964; 40 Suppl 180: 373–82
- Ogles B. M., Lambert M. J., Sawyer J. D. Clinical significance of the National Institute of Mental Health Treatment of Depression Collaborative Research Program data. J Consult Clin Psychol 1995; 63: 321–6
- Kringlen E. The prognosis in obsessional illness, a follow-up study. Acta Psyciatr Scand 1964; 40 Suppl 180: 155–7
- Strassman R. J. Adverse reactions to psychedelic drugs a review of literature. J Nerv Ment Dis 1984; 172: 577–95
- Dishotsky N. I., Loughman W. D., Mogar R. E., Lipscomb W. R. LSD and genetic damage. Science 1971; 172: 3982
- Johnsen G. Psykolytisk terapi. Psykoterapi-metoder II, R. Alnaes, G John-Sen. Fab-ritius, Oslo 1968; 155–69
- Brandrup E., Vanggaard T. LSD treatment in a severe case of compulsive neurosis. Acta Psyciatr Scand 1977; 55: 127–41
- Peroutka S. J. 5-Hydroxytryptamine receptor interactions of D-lysergic acid diethylamide. 50 years of LSD, current status and perspectives of hallucinogens, A Plet-Scher, D. Ladewig. The Parthenon publishing Group, New York 1994; 19–26
- Hermle L., Fünfgeld M., Oepen G., Botsch H., Bor-Chardt D, Gouzoulis E. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992; 32: 976–91
- Vollenweider F. X. Cerebraler Energiemetabolismus (PET,FDG) bei gesunden Probanden während Ketamin- und Psilocybin-induzierten Modell-psychosen. Fortschr Neurol Psychiatr 1992; 60: 103
- Pöldinger W. 50 Jahre LSD. Schweiz Arch Neurol Psychiatr 1993; 144: 143–5
- Steketee G. S. Treatment of obsessive compulsive disorder. The Guilford Press, New York 1993
- McDougle C. J., Goodman W. K., Price L. H. The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry 1993; Suppl 26: 24–9